NASDAQ:GNLX Genelux Q3 2026 Earnings Results & Report $2.00 +0.08 (+4.17%) Closing price 11/17/2026 04:00 PM EasternExtended Trading$2.03 +0.03 (+1.70%) As of 11/17/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Genelux missed analyst earnings expectations in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$0.23 versus the -$0.1983 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 16, 2026TimeAfter Market ClosesConference Call7:00 AM ET Genelux EPS ResultsActual EPS-$0.23Consensus EPS -$0.1983Beat/MissMissed by -$0.0317One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersGenelux Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsGenelux's Q4 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Genelux Q3 2026 Earnings FAQ Did Genelux beat earnings estimates for Q3 2026? Genelux (NASDAQ:GNLX) reported earnings of -$0.23 per share for Q3 2026, missing the consensus estimate of -$0.1983. The report was announced on Monday, November 16, 2026. When is Genelux's next earnings date? Genelux's next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for Genelux on the company's earnings history page. Genelux Earnings HeadlinesGenelux Corporation Reports Third Quarter Financial Results and Provides Business UpdatesNovember 16 at 4:14 PM | globenewswire.comGenelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed ...September 9, 2026 | markets.businessinsider.comA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years. | Profits Run (Ad)Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed ImmunochemotherapySeptember 9, 2026 | globenewswire.comGenelux Reports Second Quarter 2026 Results and Advances Olvi-Vec Clinical Programs in Ovarian and Lung CancerAugust 13, 2026 | quiverquant.comQGenelux Corporation Reports Second Quarter Financial Results and Provides Business UpdatesAugust 13, 2026 | globenewswire.comSee More Genelux Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Genelux? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genelux and other key companies, straight to your email. Email Address About GeneluxGenelux (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its research centers on engineered viruses designed to target and destroy cancer cells while stimulating an immune response against tumors. The company’s lead candidate is olvimulogene nanivacirepvec, also known as Olvi-Vec, an engineered vaccinia virus being studied in clinical trials for ovarian cancer and other solid tumors. Genelux is also advancing additional candidates based on its oncolytic virus platform. Headquartered in Westlake Village, California, Genelux conducts research and clinical development of its therapies. Its work is focused on evaluating whether oncolytic viruses can offer new treatment options for people with cancer.View Genelux ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026)Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.